» Articles » PMID: 38332914

The 'analysis of Gene Expression and Biomarkers for Point-of-care Decision Support in Sepsis' Study; Temporal Clinical Parameter Analysis and Validation of Early Diagnostic Biomarker Signatures for Severe Inflammation Andsepsis-SIRS Discrimination

Overview
Journal Front Immunol
Date 2024 Feb 9
PMID 38332914
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Early diagnosis of sepsis and discrimination from SIRS is crucial for clinicians to provide appropriate care, management and treatment to critically ill patients. We describe identification of mRNA biomarkers from peripheral blood leukocytes, able to identify severe, systemic inflammation (irrespective of origin) and differentiate Sepsis from SIRS, in adult patients within a multi-center clinical study.

Methods: Participants were recruited in Intensive Care Units (ICUs) from multiple UK hospitals, including fifty-nine patients with abdominal sepsis, eighty-four patients with pulmonary sepsis, forty-two SIRS patients with Out-of-Hospital Cardiac Arrest (OOHCA), sampled at four time points, in addition to thirty healthy control donors. Multiple clinical parameters were measured, including SOFA score, with many differences observed between SIRS and sepsis groups. Differential gene expression analyses were performed using microarray hybridization and data analyzed using a combination of parametric and non-parametric statistical tools.

Results: Nineteen high-performance, differentially expressed mRNA biomarkers were identified between control and combined SIRS/Sepsis groups (FC>20.0, p<0.05), termed 'indicators of inflammation' (I°I), including CD177, FAM20A and OLAH. Best-performing minimal signatures e.g. FAM20A/OLAH showed good accuracy for determination of severe, systemic inflammation (AUC>0.99). Twenty entities, termed 'SIRS or Sepsis' (S°S) biomarkers, were differentially expressed between sepsis and SIRS (FC>2·0, p-value<0.05).

Discussion: The best performing signature for discriminating sepsis from SIRS was CMTM5/CETP/PLA2G7/MIA/MPP3 (AUC=0.9758). The I°I and S°S signatures performed variably in other independent gene expression datasets, this may be due to technical variation in the study/assay platform.

Citing Articles

Sialyl Lewis Glycomimetics as E- and P-Selectin Antagonists Targeting Hyperinflammation.

Joyal M, Simard R, Maharsy W, Prevost M, Nemer M, Guindon Y ACS Med Chem Lett. 2025; 16(1):64-71.

PMID: 39811128 PMC: 11726361. DOI: 10.1021/acsmedchemlett.4c00452.

References
1.
Zhang J, Xu W, Xing X, Chen L, Zhao Q, Wang Y . ARG1 as a promising biomarker for sepsis diagnosis and prognosis: evidence from WGCNA and PPI network. Hereditas. 2022; 159(1):27. PMC: 9219214. DOI: 10.1186/s41065-022-00240-1. View

2.
McClain M, Constantine F, Henao R, Liu Y, Tsalik E, Burke T . Dysregulated transcriptional responses to SARS-CoV-2 in the periphery. Nat Commun. 2021; 12(1):1079. PMC: 7889643. DOI: 10.1038/s41467-021-21289-y. View

3.
Santana K, Righetti R, de Souza Breda C, Dominguez-Amorocho O, Ramalho T, Dantas F . Cholesterol-Ester Transfer Protein Alters M1 and M2 Macrophage Polarization and Worsens Experimental Elastase-Induced Pulmonary Emphysema. Front Immunol. 2021; 12:684076. PMC: 8334866. DOI: 10.3389/fimmu.2021.684076. View

4.
Sutherland A, Thomas M, Brandon R, Brandon R, Lipman J, Tang B . Development and validation of a novel molecular biomarker diagnostic test for the early detection of sepsis. Crit Care. 2011; 15(3):R149. PMC: 3219023. DOI: 10.1186/cc10274. View

5.
Mathias B, Delmas A, Ozrazgat-Baslanti T, Vanzant E, Szpila B, Mohr A . Human Myeloid-derived Suppressor Cells are Associated With Chronic Immune Suppression After Severe Sepsis/Septic Shock. Ann Surg. 2016; 265(4):827-834. PMC: 5102824. DOI: 10.1097/SLA.0000000000001783. View